Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1266 • 2016 ACR/ARHP Annual Meeting
Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Till Uhlig¹, Hilde B. Hammer², D van der Heijde^1,3, Tore K. Kvien¹, Espen Haavardsholm¹ and ARCTIC study group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: With implementation of tight control strategies and defined treatment targets in rheumatoid arthritis (RA) care, a majority of early RA patients may reach remission…
Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu⁹, Leon Gervitz¹⁰, Luke Peterson⁸ and Josef Smolen¹¹, ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…
Abstract Number: 153 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Ultrasonography: A Contemporaneous Study of Different Compartments of the Knee Joint
Aurélie Najm^1,2, Carl Orr³, Benoît Le Goff MD PhD¹, Ursula Fearon⁴ and Douglas J. Veale⁵, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁴Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁵Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland
Background/Purpose: Histological analysis of synovial tissue, despite being a reliable and accurate assessment for synovitis, is not routinely performed. Ultrasonography (US) is a fast, available…
Abstract Number: 1271 • 2016 ACR/ARHP Annual Meeting
Plasma Concentration of S100A8/A9 Proteins Is an Independent Biomarker for Radiological Progression in in Early Rheumatoid Arthritis
Maxime Chevreau¹, Marie Helène Paclet², Jean-Louis Quesada³, Marine Clay⁴, Philippe Dieudé^5,6, Olivier Vittecoq⁷, Philippe Gaudin⁸ and Athan Baillet⁹, ¹Rheumatology, CHU Sud Hospital, Grenoble, France, ²IPB _ Grenoble teaching hospital, Grenoble, France, ³Grenoble University Hospital, France, Grenoble, France, Grenoble, France, ⁴Rheumatology Grenoble, Grenoble, France, ⁵Rheumatology, Bichat hospital APHP, Paris, France, ⁶Rheumatology, Hôpital Bichat, Paris, France, ⁷Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ⁸Grenoble University Hospital, France, Grenoble, France, ⁹Rheumatology, Grenoble University Hospital, France, Echirolles, France
Background/Purpose: Increasing body of evidence suggest that alarmins such as S100A8/A9 proteins play a critical role in Rheumatoid Arthritis pathogenesis (RA). We aimed to analyze…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 163 • 2016 ACR/ARHP Annual Meeting
Fluorescence Optical Imaging Reveals Distinct Patterns of Hand Joint Inflammation in Seropositive and Seronegative Early Rheumatoid Arthritis
Yogan Kisten¹, Erik af Klint², Hamed Rezaei^2,3, Adrian Levitsky⁴, Per T Larsson², Anna Karlsson^2,3, Noémi Györi¹, Ronald F. van Vollenhoven^1,5 and Laurent Arnaud³, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁵Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands
Background/Purpose: Detection of abnormal Rheumatoid Arthritis (RA) related autoantibodies, Rheumatoid Factor (RF) and Anti- Citrullinated Peptide Antibody (ACPA), along with musculoskeletal ultrasound (MSUS) plays a…
Abstract Number: 1274 • 2016 ACR/ARHP Annual Meeting
The Reproducibility of a Semi-Automatic Algorithm in the Detection of Cortical Breaks and Adjacent Trabecular Bone Loss in Scan-Rescan Data from Patients with Early Arthritis
M. Peters¹, J. de Jong², A. Scharmga¹, A. van Tubergen¹, D. Loeffen³, R. Weijers³, B. van Rietbergen⁴, Steven K. Boyd⁵, Cheryl Barnabe⁶, Kathryn S. Stok⁷, Piet Geusens⁸ and J. van den Bergh⁹, ¹Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Maastricht University, Maastricht, Netherlands, ³Department of Radiology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Biomedical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁷Institute for Biomechanics, ETH Zurich, Zurich, Switzerland, ⁸Maastricht University Hospital, Maastricht, Netherlands, ⁹Internal Medicine, Viecuri Medical Center, Venlo, Netherlands
Background/Purpose: In RA bone erosions are defined as cortical breaks with adjacent trabecular bone loss. High resolution peripheral quantitative CT (HR-pQCT) is more sensitive than…
Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Laura Kuusalo^1,2, Hannu Kautiainen³, Tuulikki Sokka-Isler⁴, Toini Uutela⁵, Laura Pirilä², Timo Yli-Kerttula⁶, Markku J Kauppi^7,8, Tuomas Rannio⁹, Kirsi Paalanen¹⁰, Arto Kokko⁹, Juha Asikainen⁹, Jelena Borodina¹⁰, Johanna Paltta², Kari Laiho¹¹, Andrus Mullanmaa¹², Kari Puolakka¹² and SandRA Study Group, ¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Lapland Central Hospital, Rovaniemi, Finland, ⁶Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁷School of Medicine, University of Tampere, Tampere, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹⁰Jyvaskyla Central Hospital, Jyvaskyla, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland, ¹²South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
Abstract Number: 185 • 2016 ACR/ARHP Annual Meeting
The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Faye A H Cooles¹, Amy E. Anderson¹, Dennis W Lendrem¹, Julie Norris¹, Arthur G. Pratt¹, Catharien M U Hilkens² and John D Isaacs³, ¹Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: Type 1 interferons, such as interferon-α, are of increasing interest in autoimmunity due to their pleiotropic effects on the immune system. Approximately 20-30% of…
Abstract Number: 1300 • 2016 ACR/ARHP Annual Meeting
MRI-Detected Inflammation Is Associated with Functional Disability in Early Arthritis – Results of a Cross-Sectional Study
Leonie E Burgers¹, Wouter P Nieuwenhuis¹, Hanna W van Steenbergen¹, Elize C Newsum¹, Tom WJ Huizinga¹, Monique Reijnierse², Saskia le Cessie³ and Annette HM van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Department of Medical Statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Magnetic resonance imaging (MRI) sensitively detects inflammation, but the clinical relevance of MRI-detected inflammation is undetermined in early arthritis. Therefore, this cross-sectional study investigated…
Abstract Number: 3154 • 2016 ACR/ARHP Annual Meeting
Assessing Bone Erosions in the Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis: a Comparison Between MRI and Ultrasound
Karen A. Beattie¹, Sydney Scheffler², George Ioannidis³, Edward Schreyer⁴, Saara Totterman⁵ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴QMetrics Technologies, Rochester, NY, ⁵Radiology, VirtualScopics Inc., Rochester, NY
Background/Purpose: This cross-sectional study aimed to assess the agreement between Magnetic Resonance Imaging (MRI) and ultrasound (US) findings of bone erosions in the metatarsalphalangeal (MTP)…
Abstract Number: 492 • 2016 ACR/ARHP Annual Meeting
Calprotectin Levels Correlate with Inflammation in Early Rheumatoid Arthritis before Disease-Modifying Antirheumatic Drug Treatment and after 12 Months of Treatment
Maria K. Jonsson^1,2,3, Hilde B. Hammer⁴, Hilde H. Nordal^1,3, Anna-Birgitte Aga², Inge C Olsen², Karl Albert Brokstad³, Tore K Kvien², Bjørg-Tilde Fevang^1,5, Siri Lillegraven², Espen A. Haavardsholm² and ARCTIC study group, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Clinical Sciences, University of Bergen, Bergen, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a major leukocyte protein previously shown to be associated with disease activity in patients with established rheumatoid arthritis (RA). Some…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…
Abstract Number: 3209 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients
Gülsah Akdemir¹, L. Heimans², R.J. Goekoop³, Maikel van Oosterhout⁴, J.B. Harbers⁵, C. Bijkerk⁶, G.M. Steup-Beekman⁷, L.R. Lard⁸, P.B.J. de Sonnaville⁹, B.A.M. Grillet¹⁰, TWJ Huizinga¹¹ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁶Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁷Rheumatology, Bronovo Hospital, The Hague, Netherlands, ⁸Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands, ⁹Rheumatology, ADRZ, Goes, Netherlands, ¹⁰Rheumatology, Zorgsaam, Terneuzen, Netherlands, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: To assess clinical and radiological outcomes of induction therapy followed by 5 years disease activity score (DAS)-remission steered treatment in early arthritis patients. Methods:…
Abstract Number: 501 • 2016 ACR/ARHP Annual Meeting
Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Dilpreet Singh¹, Jasdeep Badwal¹, Ritika Vankina¹, Santhi Gokaraju², Jennifer Friderici³, Scott Halista⁴ and Tara Lagu¹, ¹Baystate Medical Center/Tufts University School of Medicine, Springfield, MA, ²Presbyterian Hospital of Dallas, Dallas, TX, ³Baystate Medical Center, Springfield, MA, ⁴Arthritis Treatment Center, Springfield, MA
Background/Purpose: Anti-cyclic citrullinated peptide antibody (Anti-CCP) is a diagnostic tool that predicts the progression of undifferentiated polyarthritis and erosive disease in rheumatoid arthritis (RA). It…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.